Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sichuan Kelun Pharmaceutical Co. Ltd.

en.kelun.com

Latest From Sichuan Kelun Pharmaceutical Co. Ltd.

Venture Funding Deals: Orchard Brings Total To $291m

New $150m Series C round brings Orchard's tally to nearly $300m, just four months after the start-up acquired a portfolio of gene therapy candidates from GSK and eight months after a $110m round. Gritstone closed a Series C then announced an IPO filing, plus more late-summer VC rounds.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Sichuan Kelun Pharmaceutical Co. Ltd.
  • Senior Management
  • Tongtong Xue, CEO
  • Contact Info
  • Sichuan Kelun Pharmaceutical Co. Ltd.
    Phone: 28 8299 8999
    No. 36 W. Baihua Rd. Qingying District
    Chengdu
    Sichuan, 610071
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register